Victory Capital Management Inc. Has $17.89 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 31.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 98,285 shares of the company's stock after selling 45,580 shares during the period. Victory Capital Management Inc. owned about 0.34% of Krystal Biotech worth $17,891,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KRYS. Price T Rowe Associates Inc. MD grew its stake in shares of Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company's stock valued at $117,189,000 after buying an additional 231,255 shares during the period. Dimensional Fund Advisors LP increased its stake in Krystal Biotech by 1.3% during the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company's stock worth $106,593,000 after acquiring an additional 7,537 shares during the last quarter. Hood River Capital Management LLC raised its holdings in shares of Krystal Biotech by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company's stock worth $95,694,000 after purchasing an additional 25,507 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock valued at $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Krystal Biotech by 11.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company's stock worth $32,402,000 after purchasing an additional 18,021 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on KRYS shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital lifted their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a report on Monday, August 5th. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. William Blair raised Krystal Biotech to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $197.00.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.10% of the company's stock.

Krystal Biotech Stock Up 1.3 %

Shares of KRYS stock traded up $2.21 during trading hours on Tuesday, reaching $177.85. 215,825 shares of the stock traded hands, compared to its average volume of 328,296. The firm has a market capitalization of $5.11 billion, a PE ratio of 99.23 and a beta of 0.82. Krystal Biotech, Inc. has a 1-year low of $99.00 and a 1-year high of $219.34. The business has a fifty day moving average price of $180.59 and a 200 day moving average price of $181.90.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same period last year, the company posted ($0.67) EPS. The business's quarterly revenue was up 879.9% compared to the same quarter last year. Research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).